Crystal Structure of a Complex of the Intracellular Domain of Interferon λ Receptor 1 (IFNLR1) and the FERM/SH2 Domains of Human JAK1

Journal of Molecular Biology

Volumn 428, Issue 23, 2016, Pages 4651-4668

  Zhang, Di ^a   Wlodawer, Alexander ^a   Lubkowski, Jacek ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cytokine receptors; JAK STAT signaling; Janus kinases; protein protein interactions; structure comparisons

Indexed keywords

ALPHA INTERFERON RECEPTOR; CARBOXYLIC ACID; EPITOPE; FERM PROTEIN; GLUTAMIC ACID; GUANIDINE; HYDROGEN; IMIDAZOLE; INTERFERON LAMBDA RECEPTOR 1; INTERFERON RECEPTOR; JANUS KINASE 1; LYSINE; PHOSPHOTYROSINE; PROTEIN; PROTEIN KINASE TYK2; PROTEIN SH2; UNCLASSIFIED DRUG; CYTOKINE RECEPTOR; IFNLR1 PROTEIN, HUMAN; JAK1 PROTEIN, HUMAN; PROTEIN BINDING;

AMINO ACID SEQUENCE; ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; ELECTRON; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; RADIATION INJURY; RECEPTOR BINDING; STRUCTURE ANALYSIS; SURFACE AREA; X RAY DIFFRACTION; CHEMISTRY; METABOLISM; MOLECULAR MODEL; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; HUMANS; JANUS KINASE 1; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, CYTOKINE;

EID: 84995549478     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2016.10.005     Document Type: Article

References (44)

1. [1] O'Sullivan, L.A., Liongue, C., Lewis, R.S., Stephenson, S.E., Ward, A.C., Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol. Immunol. 44 (2007), 2497–2506.
2. [2] Haan, C., Behrmann, I., Haan, S., Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J. Cell. Mol. Med. 14 (2010), 504–527.
3. [3] O'Shea, J.J., Plenge, R., JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36 (2012), 542–550.
4. [4] Schwartz, D.M., Bonelli, M., Gadina, M., O'Shea, J.J., Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat. Rev. Rheumatol. 12 (2016), 25–36.
5. [5] de Vos, A.M., Ultsch, M., Kossiakoff, A.A., Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255 (1992), 306–312.
6. [6] Brooks, A.J., Dai, W., O'Mara, M.L., Abankwa, D., Chhabra, Y., Pelekanos, R.A., et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science, 344, 2014, 1,249,783.
7. [7] Babon, J.J., Lucet, I.S., Murphy, J.M., Nicola, N.A., Varghese, L.N., The molecular regulation of Janus kinase (JAK) activation. Biochem. J. 462 (2014), 1–13.
8. [8] Walsh, S.T., Structural insights into the common gamma-chain family of cytokines and receptors from the interleukin-7 pathway. Immunol. Rev. 250 (2012), 303–316.
9. [9] Broughton, S.E., Dhagat, U., Hercus, T.R., Nero, T.L., Grimbaldeston, M.A., Bonder, C.S., et al. The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol. Rev. 250 (2012), 277–302.
10. [10] Zdanov, A., Structural analysis of cytokines comprising the IL-10 family. Cytokine Growth Factor Rev. 21 (2010), 325–330.
11. [11] Zdanov, A., Structure and function of IL-10 and IL-10 receptor. Marincola, F., (eds.) Interleukin-10: Landes Bioscience, 2006, 1–10.
12. [12] Chow, D., He, X., Snow, A.L., Rose-John, S., Garcia, K.C., Structure of an extracellular gp130 cytokine receptor signaling complex. Science 291 (2001), 2150–2155.
13. [13] Wang, X., Lupardus, P., Laporte, S.L., Garcia, K.C., Structural biology of shared cytokine receptors. Annu. Rev. Immunol. 27 (2009), 29–60.
14. [14] Spangler, J.B., Moraga, I., Mendoza, J.L., Garcia, K.C., Insights into cytokine-receptor interactions from cytokine engineering. Annu. Rev. Immunol. 33 (2015), 139–167.
15. [15] Boggon, T.J., Li, Y., Manley, P.W., Eck, M.J., Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 106 (2005), 996–1002.
16. [16] Ungureanu, D., Wu, J., Pekkala, T., Niranjan, Y., Young, C., Jensen, O.N., et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18 (2011), 971–976.
17. [17] Wallweber, H.J., Tam, C., Franke, Y., Starovasnik, M.A., Lupardus, P.J., Structural basis of recognition of interferon-alpha receptor by tyrosine kinase 2. Nat. Struct. Mol. Biol. 21 (2014), 443–448.
18. [18] Ferrao, R., Wallweber, H.J., Ho, H., Tam, C., Franke, Y., Quinn, J., et al. The structural basis for class II cytokine receptor recognition by JAK1. Structure 24 (2016), 897–905.
19. [19] McNally, R., Toms, A.V., Eck, M.J., Crystal structure of the FERM-SH2 module of human Jak2. PLoS One, 11, 2016, e0156218.
20. [20] Brand, S., Beigel, F., Olszak, T., Zitzmann, K., Eichhorst, S.T., Otte, J.M., et al. IL-28 A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am. J. Physiol. Gastrointest. Liver Physiol. 289 (2005), G960–G968.
21. [21] Meager, A., Visvalingam, K., Dilger, P., Bryan, D., Wadhwa, M., Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 31 (2005), 109–118.
22. [22] Zitzmann, K., Brand, S., Baehs, S., Goke, B., Meinecke, J., Spottl, G., et al. Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem. Biophys. Res. Commun. 344 (2006), 1334–1341.
23. [23] Miknis, Z.J., Magracheva, E., Li, W., Zdanov, A., Kotenko, S.V., Wlodawer, A., Crystal structure of human interferon-lambda1 in complex with its high-affinity receptor interferon-lR1. J. Mol. Biol. 404 (2010), 650–664.
24. [24] Dumoutier, L., Tounsi, A., Michiels, T., Sommereyns, C., Kotenko, S.V., Renauld, J.C., Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J. Biol. Chem. 279 (2004), 32,269–32,274.
25. [25] Murakami, M., Narazaki, M., Hibi, M., Yawata, H., Yasukawa, K., Hamaguchi, M., et al. Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc. Natl. Acad. Sci. U. S. A. 88 (1991), 11,349–11,353.
26. [26] Usacheva, A., Sandoval, R., Domanski, P., Kotenko, S.V., Nelms, K., Goldsmith, M.A., et al. Contribution of the box 1 and box 2 motifs of cytokine receptors to Jak1 association and activation. J. Biol. Chem. 277 (2002), 48,220–48,226.
27. [27] Haan, C., Heinrich, P.C., Behrmann, I., Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation. Biochem. J. 361 (2002), 105–111.
28. [28] Floss, D.M., Klocker, T., Schroder, J., Lamertz, L., Mrotzek, S., Strobl, B., et al. Defining the functional binding sites of interleukin 12 receptor beta1 and interleukin 23 receptor to Janus kinases. Mol. Biol. Cell 27 (2016), 2301–2316.
29. [29] Wilks, A.F., Harpur, A.G., Kurban, R.R., Ralph, S.J., Zurcher, G., Ziemiecki, A., Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol. Cell. Biol. 11 (1991), 2057–2065.
30. [30] Kampa, D., Burnside, J., Computational and functional analysis of the putative SH2 domain in Janus kinases. Biochem. Biophys. Res. Commun. 278 (2000), 175–182.
31. [31] Radtke, S., Haan, S., Jorissen, A., Hermanns, H.M., Diefenbach, S., Smyczek, T., et al. The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. J. Biol. Chem. 280 (2005), 25,760–25,768.
32. [32] Richter, M.R., Dumenil, G., Uze, G., Fellous, M., Pellegrini, S., Specific contribution of Tyk2 JH regions to the binding and the expression of the interferon α/β receptor component IFNAR1. J. Biol. Chem. 273 (1998), 24,723–24,729.
33. [33] Strong, M., Sawaya, M.R., Wang, S., Phillips, M., Cascio, D., Eisenberg, D., Toward the structural genomics of complexes: crystal structure of a PE/PPE protein complex from Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 8060–8065.
34. [34] Otwinowski, Z., Minor, W., Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997), 307–326.
35. [35] Minor, W., Cymborowski, M., Otwinowski, Z., Chruszcz, M., HKL-3000: the integration of data reduction and structure solution—from diffraction images to an initial model in minutes. Acta Crystallogr. D62 (2006), 859–866.
36. [36] McCoy, A.J., Solving structures of protein complexes by molecular replacement with Phaser. Acta Crystallogr. D63 (2007), 32–41.
37. [37] Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N., et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D66 (2010), 213–221.
38. [38] DiMaio, F., Terwilliger, T.C., Read, R.J., Wlodawer, A., Oberdorfer, G., Wagner, U., et al. Improved molecular replacement by density and energy guided protein structure optimization. Nature 473 (2011), 540–543.
39. [39] Murshudov, G.N., Skubak, P., Lebedev, A.A., Pannu, N.S., Steiner, R.A., Nicholls, R.A., et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D67 (2011), 355–367.
40. [40] Perrakis, A., Morris, R., Lamzin, V.S., Automated protein model building combined with iterative structure refinement. Nat. Struct. Biol. 6 (1999), 458–463.
41. [41] Emsley, P., Cowtan, K., Coot: model-building tools for molecular graphics. Acta Crystallogr. D60 (2004), 2126–2132.
42. [42] DeLano, W.L., The PyMOL Molecular Graphics System. 2002, DeLano Scientific, San Carlos, CA.
43. [43] Eck, M.J., Shoelson, S.E., Harrison, S.C., Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck. Nature 362 (1993), 87–91.
44. [44] Chen, V.B., Arendall, W.B. III, Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J., et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66 (2010), 12–21.